SCHEMBL25413193

SCHEMBL25413193

C=Cc1cc(Br)c2c(c1)C(=O)NC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 2/20 0.49
▸ DYRK1A Q13627 2/20 0.49
▸ CLK4 Q9HAZ1 2/20 0.49
▸ PIM1 P11309 1/20 0.49
▸ CSNK1A1 P48729 1/20 0.49
▸ ROCK1 Q13464 1/20 0.49
▸ LRRK2 Q5S007 1/20 0.49
▸ DYRK1B Q9Y463 1/20 0.49
▸ GRM2 Q14416 1/20 0.34
▸ CISD1 Q9NZ45 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ PARP10 Q53GL7 1/20 0.33
▸ PARP11 Q9NR21 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ CA12 O43570 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ LTK P29376 1/20 0.30
▸ MST1R Q04912 1/20 0.30
▸ PARP1 P09874 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25415363 0.85 CDK5 (0.50) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL30598935 0.85 CDK5 (0.50) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL27085777 0.81 GRM2 (0.41) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL32686477 0.80 CLK1 (0.35) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL30598973 0.76 HTR2A (0.38) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL25186469 0.76 HTR2A (0.38) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL27085824 0.76 MEN1 (0.40) DYRK1ACLK4PIM1CISD1KMT2A
SCHEMBL24147834 0.74 CLK4 (0.53) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL1334392 0.74 CLK4 (0.53) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL25411512 0.74 CLK4 (0.53) CDK5DYRK1ACLK4PIM1CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2025-10-02 — — US disclosed
EP-4490152-A1 ACTIVATORS OF EFFECTOR T CELLS Orum Therapeutics Inc. (KR) 2025-01-15 — — EP disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 — — WO disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS CBLB, CBL, CBLC CDK5 1317/4885DYRK1A 352/4885CLK4 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback